NCT05531123View on ClinicalTrials.gov

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 10, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions
Bladder Cancer
Interventions
DRUG

Tislelizumab

Tislelizumab 200 mg I.V. Q3W on the day 1

DRUG

gemcitabine and cisplatin

Cisplatin 70mg/m2 I.V. Q3W on the day 1, dose fractionation is allowed ;Gemcitabine 1000mg/m2 I.V. Q3W on the day 1 and day 8

RADIATION

Modified hypofractionation

"* Whole bladder 44Gy / 16fractionation (If N1: Whole bladder + Pelvic nodes 44Gy / 16fractionation) (Positive lymph nodes can be dosed to the maximum tolerable dose)~* Tumor boost 11Gy / 4fractionation~* Radiosensitizing chemotherapy: DDP 75-80 mg/m2 weekly Q3W"

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER